OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
PIKture-01 Trial Updates: OnKure Therapeutics is set to provide additional data from the PIKture-01 trial, including safety and pharmacokinetic results for its lead drug OKI-219, with updates expected in the second half of 2025. The company has also initiated a combination study with fulvestrant and plans to announce a new pan-mutant selective program by Q2 2025.
Financial Overview: As of December 31, 2024, OnKure reported approximately $110.8 million in cash, sufficient to fund operations through multiple clinical readouts into Q4 2026. The company experienced increased R&D expenses and reported a net loss of $17.4 million for the fourth quarter of 2024.
Trade with 70% Backtested Accuracy
Analyst Views on OKUR
About OKUR
About the author
VTI ETF Update, October 9, 2025
VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 1.59% over the past week and 14.80% year-to-date, with a Moderate Buy consensus from analysts and a price target suggesting a 10.88% upside.
Holdings Analysis: VTI's top five holdings with the highest upside potential include Cibus, FibroBiologics, and Biodesix, while those with the greatest downside risk include Wolfspeed and Opendoor Technologies.
VTI ETF Update, October 8, 2025
VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 0.69% over the past week and 14.80% year-to-date, with a Moderate Buy consensus from analysts and a price target suggesting a 12.21% upside.
Holdings Analysis: VTI's top five holdings with the highest upside potential include Biodesix and Cibus, while those with the greatest downside risk include Wolfspeed and Opendoor Technologies; overall, VTI's Smart Score indicates it will likely perform in line with the market.
VTI ETF Update, October 7, 2025
VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 1.15% over the past week and 14.92% year-to-date, with a Moderate Buy rating from analysts and a price target suggesting an 11.18% upside.
Holdings Analysis: VTI's top five holdings with the highest upside potential include Cibus and Biodesix, while those with the greatest downside risk include Wolfspeed and GoPro.
HC Wainwright & Co. Affirms Buy Rating for OnKure Therapeutics, Keeps $34 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
Trial Progress and Financial Outlook: OnKure Therapeutics is making progress in its PIKture-01 trial, with plans to report additional data in late 2025. The company has $96.7 million in cash, expected to fund operations through Q4 2026.
Development of New Candidates: OnKure is advancing its PI3K franchise, aiming to announce a pan-mutant selective development candidate by Q2 2025, while also reporting positive preliminary results from the ongoing trials of its lead drug, OKI-219.
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Analyst Rating Changes: Various Wall Street analysts have adjusted their price targets for several companies, with Citigroup lowering AvePoint's target from $18 to $16 while maintaining a Neutral rating, and BMO Capital raising Protagonist Therapeutics' target from $62 to $72 with an Outperform rating.
Stock Performance Updates: Other notable changes include Stifel cutting DarioHealth's target to $2 but keeping a Buy rating, and Morgan Stanley increasing Gilead Sciences' target to $130 while maintaining an Overweight rating.
VTI ETF Update, October 9, 2025
VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 1.59% over the past week and 14.80% year-to-date, with a Moderate Buy consensus from analysts and a price target suggesting a 10.88% upside.
Holdings Analysis: VTI's top five holdings with the highest upside potential include Cibus, FibroBiologics, and Biodesix, while those with the greatest downside risk include Wolfspeed and Opendoor Technologies.
VTI ETF Update, October 8, 2025
VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 0.69% over the past week and 14.80% year-to-date, with a Moderate Buy consensus from analysts and a price target suggesting a 12.21% upside.
Holdings Analysis: VTI's top five holdings with the highest upside potential include Biodesix and Cibus, while those with the greatest downside risk include Wolfspeed and Opendoor Technologies; overall, VTI's Smart Score indicates it will likely perform in line with the market.
VTI ETF Update, October 7, 2025
VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 1.15% over the past week and 14.92% year-to-date, with a Moderate Buy rating from analysts and a price target suggesting an 11.18% upside.
Holdings Analysis: VTI's top five holdings with the highest upside potential include Cibus and Biodesix, while those with the greatest downside risk include Wolfspeed and GoPro.
HC Wainwright & Co. Affirms Buy Rating for OnKure Therapeutics, Keeps $34 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
Trial Progress and Financial Outlook: OnKure Therapeutics is making progress in its PIKture-01 trial, with plans to report additional data in late 2025. The company has $96.7 million in cash, expected to fund operations through Q4 2026.
Development of New Candidates: OnKure is advancing its PI3K franchise, aiming to announce a pan-mutant selective development candidate by Q2 2025, while also reporting positive preliminary results from the ongoing trials of its lead drug, OKI-219.
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Analyst Rating Changes: Various Wall Street analysts have adjusted their price targets for several companies, with Citigroup lowering AvePoint's target from $18 to $16 while maintaining a Neutral rating, and BMO Capital raising Protagonist Therapeutics' target from $62 to $72 with an Outperform rating.
Stock Performance Updates: Other notable changes include Stifel cutting DarioHealth's target to $2 but keeping a Buy rating, and Morgan Stanley increasing Gilead Sciences' target to $130 while maintaining an Overweight rating.
